Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus.

@article{Berria2007ReductionIH,
  title={Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus.},
  author={Rachele Berria and Leonard Glass and Archana Mahankali and Yusuke Miyazaki and A. L. Velasco Monroy and Eleanna De Filippis and Kenneth Cusi and Eugenio Cersosimo and Ralph A DeFronzo and Amalia Gastaldelli},
  journal={Clinical pharmacology and therapeutics},
  year={2007},
  volume={82 3},
  pages={275-81}
}
Peripheral edema, mild weight gain, and anemia are often observed in type II diabetic patients treated with thiazolidinediones (TZDs). Small decreases in hemoglobin (Hb) and hematocrit (Hct) appear to be a class effect of TZDs and are generally attributed to fluid retention, although experimental data are lacking. We analyzed 50 patients with type II diabetes mellitus undergoing either placebo or pioglitazone (PIO, 45 mg/day) for 16 weeks. Before and after therapy, we measured Hb/Hct and used… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
29 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…